NeurologyLive® Mind Moments®

Special Episode: FDA Approves Sodium Oxybate for Pediatric Narcolepsy


Listen Later

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we cover the recent approval of Avadel's sodium oxybate formulation (Lumryz) as a treatment for pediatric patients with narcolepsy aged 7 years and older. The new indication expands on its previous one, granted in May 2023, which included the the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. It's initial approval was based on data from the phase 3 REST-ON trial (NCT02720744), a large-scale study in which the therapy met all 3 of its primary end points of change from baseline in mean sleep latency on the Maintenance of Wakefulness test, Clinical Global Impression Improvement, and weekly cataplexy attacks. Following its new indication, NeurologyLive sat down with Anne Marie Morse, DO, FAASM, a pediatric sleep disorders expert, to discuss the significance of the new approval. Morse, director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital as well as the program director for Child Neurology Residency Program, provided commentary on the clinical considerations behind this once-nightly formulation of sodium oxybate, and how it should be used going forward.


For more of NeurologyLive's coverage of sodium oxybate's (Lumryz) expanded indication, head here: FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy

Episode Breakdown:
  • 2:10 – Immediate reaction and significance 
  • 4:10 – Considerations and caution with prescribing sodium oxybate
  • 8:20 – Closing remarks and the need to utilize highly effective treatments for narcolepsy

    Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    ...more
    View all episodesView all episodes
    Download on the App Store

    NeurologyLive® Mind Moments®By NeurologyLive

    • 4.6
    • 4.6
    • 4.6
    • 4.6
    • 4.6

    4.6

    10 ratings


    More shows like NeurologyLive® Mind Moments®

    View all
    The Clark Howard Podcast by Clark Howard

    The Clark Howard Podcast

    5,390 Listeners

    Neurology® Podcast by American Academy of Neurology

    Neurology® Podcast

    283 Listeners

    NEJM This Week by NEJM Group

    NEJM This Week

    318 Listeners

    Practical Neurology Podcast by BMJ Group

    Practical Neurology Podcast

    45 Listeners

    JAMA Neurology Author Interviews by JAMA Network

    JAMA Neurology Author Interviews

    14 Listeners

    BMJ Best Practice Podcast by BMJ Group

    BMJ Best Practice Podcast

    28 Listeners

    Neurology Today in 5 by American Academy of Neurology

    Neurology Today in 5

    22 Listeners

    Neurology Minute by American Academy of Neurology

    Neurology Minute

    132 Listeners

    Dateline NBC by NBC News

    Dateline NBC

    48,007 Listeners

    The Ezra Klein Show by New York Times Opinion

    The Ezra Klein Show

    15,316 Listeners

    Chanticleer by Australian Financial Review

    Chanticleer

    20 Listeners

    Movers and Shakers: a podcast about life with Parkinson's by Podot

    Movers and Shakers: a podcast about life with Parkinson's

    104 Listeners

    The Top Line by Fierce Life Sciences

    The Top Line

    12 Listeners

    Continuum Audio by American Academy of Neurology

    Continuum Audio

    77 Listeners

    The Economics Show by Financial Times

    The Economics Show

    96 Listeners